Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986278 Bioavailability, Food Effect, and DDI Study
NCT04468815Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2020
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of admilparant in idiopathic pulmonary fibrosis (IPF) and pulmonary fibrosis (PF) (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum plasma concentration up to 5 days, Area under the concentration-time curve from time 0 to last quantifiable concentration up to 5 days and 1 more. Started Jul 2020; status: completed.
02
Drugs
admilparant
03
Conditions
idiopathic pulmonary fibrosis (IPF)pulmonary fibrosis (PF)
Beyond the preview
Go deeper on NCT04468815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04468815.